Zymeworks Inc. Stock Prediction
AI-powered sentiment analysis and prediction trends for ZYME, updated each market day.
ZYME AI Sentiment
AI sees no strong directional signal for Zymeworks Inc. stock over the next 10 market days.
Prediction date: April 10, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About Zymeworks Inc.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. It is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.
Sector
Exchange
Market Cap
$2,032,181,333
Cap Tier
Employees
264
Headquarters
MIDDLETOWN, DE
Listed Since
April 28, 2017
Website
ZYME Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
ZYME Volatility
Zymeworks Inc. has shown moderate price volatility over the last 5 trading days. Moderate volatility indicates normal market activity with typical price fluctuations.
